Age Related Macular Degeneration Global Clinical Trials Review, H1, 2017

Age Related Macular Degeneration Global Clinical Trials Review, H1, 2017


  • Products Id :- GDHC4098CTIDB
  • |
  • Pages: 489
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Age Related Macular Degeneration Global Clinical Trials Review, H1, 2017

Summary

GlobalData's clinical trial report, "Age Related Macular Degeneration Global Clinical Trials Review, H1, 2017" provides an overview of Age Related Macular Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Age Related Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Five Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Age Related Macular Degeneration to Ophthalmology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Age Related Macular Degeneration to Ophthalmology Clinical Trials 18

Clinical Trials by Phase in E7 Countries 20

Clinical Trials in E7 Countries by Trial Status 21

Clinical Trials by Phase 22

In Progress Trials by Phase 23

Clinical Trials by Trial Status 24

Clinical Trials by End Point Status 25

Subjects Recruited Over a Period of Time 26

Clinical Trials by Sponsor Type 27

Prominent Sponsors 28

Top Companies Participating in Age Related Macular Degeneration Therapeutics Clinical Trials 30

Prominent Drugs 32

Latest Clinical Trials News on Age Related Macular Degeneration 33

Mar 09, 2017: Tyrogenex Completes Patient Enrollment in its Phase 2 Trial of Orally Administered Vorolanib for Wet Age-related Macular Degeneration 33

Mar 08, 2017: Opthea Completes FDA Meeting to Inform OPT-302 wet AMD Clinical Program 33

Feb 27, 2017: Xbrane Biopharma Reports Positive in-vitro Biosimilarity Data on Xlucane 33

Feb 09, 2017: Iconic Therapeutics to Present Phase 2a EMERGE Trial Results at Miami Meeting 34

Clinical Trial Profile Snapshots 35

Appendix 486

Abbreviations 486

Definitions 486

Research Methodology 487

Secondary Research 487

About GlobalData 488

Contact Us 488

Source 489

List of Figures

Age Related Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2017* 6

Age Related Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7

Age Related Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9

Age Related Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10

Age Related Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11

Age Related Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12

Age Related Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 13

Age Related Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 14

Proportion of Age Related Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2017* 15

Age Related Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16

Age Related Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17

Proportion of Age Related Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2017* 18

Age Related Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20

Age Related Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21

Age Related Macular Degeneration Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22

Age Related Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23

Age Related Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24

Age Related Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25

Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26

Age Related Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27

Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28

Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30

Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

GlobalData Methodology 487

List of Tables

Age Related Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2017* 6

Age Related Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8

Age Related Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9

Age Related Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10

Age Related Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11

Age Related Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2017* 12

Age Related Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 13

Age Related Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14

Proportion of Age Related Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2017* 15

Age Related Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16

Age Related Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17

Proportion of Age Related Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2017* 19

Age Related Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20

Age Related Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21

Age Related Macular Degeneration Therapeutics, Global, Clinical Trials by Phase, 2017* 22

Age Related Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23

Age Related Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24

Age Related Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25

Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26

Age Related Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27

Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29

Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31

Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Pfizer Inc, Ophthotech Corp, Allergan Plc, Santen Pharmaceutical Co Ltd, Novelion Therapeutics Inc, GlaxoSmithKline Plc

select a license

Single User License
USD 2500 INR 160875
Site License
USD 5000 INR 321750
Corporate User License
USD 7500 INR 482625

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com